Recruiting
Mavacamten Pregnancy Surveillance Program - CV027-014
Actualizada:
3 julio, 2023
|
ClinicalTrials.gov
Imprimir Resumen
Detalles del estudio
Géneros
Rango de edad
Ubicación (es)
Recruiting
Opciones de tratamiento
Inclusion Criteria: - Exposure to at least 1 dose of mavacamten at any time during pregnancy (from 4 months prior to conception to pregnancy outcome) and/or at any time during breastfeeding (up to 12 months of infant age or weaning, whichever comes first) - At least 15 years of age or older at the time of enrollment - Informed consent or institutional review board/ethics committee-approved waiver of informed consent Exclusion Criteria: - None
Recomendamos encarecidamente que se comunique con BMS para informar los efectos secundarios (eventos adversos)
Los efectos secundarios (eventos adversos) y otros eventos reportables se definen aquí
Informe de efectos secundarios (eventos adversos) o quejas sobre la calidad del producto: información médica